Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23950196 | 0.95 | TP53 (0.56) | TP53NLRP3KMT2ARAB9ANPC1 | |
| SCHEMBL23950198 | 0.79 | ALOX15 (0.47) | TP53NLRP3NPC1POLB | |
| SCHEMBL23950616 | 0.77 | NLRP3 (0.50) | TP53NLRP3THRBPOLBSMN1; SMN2 | |
| SCHEMBL23952381 | 0.76 | MAPT (0.65) | TP53NLRP3KMT2ARAB9ANPC1 | |
| SCHEMBL23950524 | 0.74 | KDM4E (0.47) | KMT2APOLBSMN1; SMN2 | |
| SCHEMBL23950203 | 0.73 | PIK3CA (0.39) | TP53NLRP3NPC1POLB | |
| SCHEMBL25633990 | 0.73 | THRB (0.77) | TP53NLRP3KMT2ARAB9ANPC1 | |
| SCHEMBL23950622 | 0.72 | POLB (0.60) | TP53KMT2ATHRBPOLBSMN1; SMN2 | |
| SCHEMBL25633954 | 0.71 | KMT2A (0.68) | TP53NLRP3KMT2ANPC1THRB | |
| SCHEMBL25633383 | 0.70 | TP53 (0.60) | TP53NLRP3KMT2ATHRBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| WO-2021209552-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | NLRP3, PYCARD, NLRP1 | TP53 2445/4885NLRP3 1/4885KMT2A 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.